Using exome sequence and questionnaire data, researchers saw links between motor skills and likely gene disruptive or missense de novo mutations.
Technology Review reports that animals given large gene therapies doses have suffered fatal side effects.
The FDA has expanded the indications for both AstraZeneca's PARP inhibitor Lynparza and Myriad Genetics' BRACAnalysis CDx test, as GenomeWeb reports.
In Nucleic Acids Research this week: Planteome database of reference plant ontologies and other data; algorithm to find rearrangements in cancer genomes; and more.
Penn bioinformaticians are testing REALGAR, an application to simplify searches of GWAS, WGS, RNA-seq, and other test results for wet-lab researchers.
University of Pennsylvania researchers sequenced single mitochondria, which they noted could be used to track the development of mitochondrial disease.
Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes.
In the African American arm of a new GWAS, a risk variant in the SEMA3A gene was associated with both alcohol dependence disorder and major depressive disorder.
A genome-wide association study involving almost 1,600 African individuals led to diverse skin pigmentation-associated loci with varied effects on the complex trait.
A new set of papers reveals a range of gene expression influencers, identified using thousands of samples collected for the Genotype-Tissue Expression project.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.